Clinical determinants of coronavirus disease COVID-19 manifestation


  • O.M. Kovalyova Kharkiv National Medical University, Kharkiv, Ukraine, Ukraine



coronavirus disease COVID-19, arterial hypertension, obesity, diabetes mellitus, cigarette smoking


The article presents the review of modern publications on the assessment of the factors which have impact on susceptibility, clinical course and outcomes of COVID-19 infection. Statistical data on rate of increased blood pressure and adverse clinical signs of infection disease in different populations are shown. The important role of angiotensin-converting enzyme 2 as functional cellular receptor for coronavirus and its participation in multiple systemic manifestations of COVID-19 are presented. The mechanisms of damage effects of cigarette smoking in virus pneumonia have been described. According to literature data, the relationship between metabolic disorders related to obesity and risk of severe coronavirus course is emphasized. From a pathophysiological point of view, an explanation is given for the occurrence of threatening complications in patients with a new coronavirus infection in the presence of diabetes mellitus — massive lung damage, acute respiratory distress syndrome, prothrombotic condition, venous and arterial thrombosis.


Bleibtreu A., Bertine M., Bertin C. et al. Focus on Middle East respiratory syndrome coronavirus (MERS-CoV). Medecine et Maladies Infectieuses. 2020. 50(3). 243-251.

Chen T., Wu D., Chen H. et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. Br. Med. J. 2020. 368. m1091. doi: 10.1136/bmj.m1091.

Chung W.S., Lin L., Kao C.H. Diabetes increases the risk of deep-vein thrombosis and pulmonary embolism. A population-based cohort study. Thromb. Haemost. 2015. 114. 812-818. doi: 10.1160/TH14-10-0868.

Clark C., Sinead T. J., McDonagh S.T.J. et al. COVID-19 and hypertension: risks and management. A scientific statement on behalf of the British and Irish Hypertension Society. Journal of Human Hypertension. 2021. 35. 304-307;

Сörtük M., Acat M., Yazici. et al. Retrospective review of epidemic viral pneumonia cases in Turkey: A multicenter study. Experimental and Therapeutic Medicine. 2017. 13(4). 1431-1437.

COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE guideline. Published: 18 December 2020. Available at:

Crowley S.D., Coffman T.M. Recent advances involving the renin-angiotensin system. Exp. Cell. Res. 2012. 318. 1049-1056.

Docherty A.B., Harrison E.M., Green C.A. et al; ISARIC4C investigators. Features of 20133 UK patients in hospital with COVID-19 using the ISARIC WHO Сlinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020. 369. m1985. doi:10.1136/bmj.m198.

Factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv. 020.

Garg S., Kim L., Whitaker M. et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 — COVID-NET, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. 2020. 69(15). 458-464. doi:10.15585/mmwr.mm6915e3.

Holman N. et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a po-pulation-based cohort study. Lancet Diabetes Endocrinol. 2020. 8. 823-833. doi: 10.1016/S2213-8587(20)30271-0.

Jiang C., Chen Q., Xie M. Smoking increases the risk of infectious diseases: A narrative review. Tobacco Induced Diseases. 2020. 18. 60.

Kass D.A., Duggal P., Cingolani O. Obesity could shift severe COVID-19 disease to younger ages. Lancet. 2020 May 16. 395(10236). 1544-1545. (accessed 12 May 2020).

Lawrence H., Hunter A., Murray R. et al. Cigarette smo-king and the occurrence of influenza -systematic review. Journal of Infection. 2019. 79(5). 401-406.

Lighter J., Phillips M., Hochman S. et al. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin. Infect. Dis. 2020. doi: 10.1093/cid/ciaa415. [published online April 9, 2020]

Liu L., Shan H., Lei C.L. et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine. 2020. 382(18). 1708-1720.

Monteil V., Prado P., Hagelkrüys A. et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020; (accessed April 17, 2020). published online in press.

Patel S.K., Velkoska E., Burrell L.M. Emerging markers in cardiovascular disease: where does angiotensin-converting enzyme 2 fit in? Clin. Exp. Pharmacol. Physiol. 2013 Aug. 40(8). 551-9. doi: 10.1111/1440-1681.12069.

Qiu F., Liang C. L., Liu H. et al. Impacts of cigarette smoking on immune responsiveness: Up and down or upside down? Oncotarget. 2017. 8(1). 268-284.

Richardson S., Hirsch J.S., Narasimhan M. et al. The Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020. 323(20). 2052-2059. doi: 10.1001/jama.2020.6775.

Rosenberg E.S., Dufort E.M., Blog D.S. et al. New York State Coronavirus 2019 Response Team. COVID-19 testing, epidemic features, hospital outcomes, and household prevalence, New York state-march 2020. Clin. Infect. Dis. 2020; doi: 10.1093/cid/ciaa549. May 8.

Sattar N., McInnes I.B., McMurray J.V. Obesity a risk factor for severe covid-19 infection: multiple potential mechanisms. Circulation. 2020. 22/4/20;

Simonnet A., Chetboun M., Poissy J. et al. Lille Intensive Care COVID-19 and Obesity Study Group. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation [published online April 9, 2020]. Obesity (Silver Spring). doi: 10.1002/oby.22831.

Soro-Paavonen A., Gordin D., Forsblom C. et al. Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. J. Hypertens. 2012 Feb. 30(2). 375-83. doi: 10.1097/HJH.0b013e32834f04b6.

Tang N., Li D., Wang X. et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 2020. 18. 844-847. doi: 10.1111/jth.14768.

The Novel Coronavirus Pneumonia Emergency Response Epidemiology. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China, 2020. China CDC Weekly. 2020. 2. 113-122.

The RECOVERY Collaborative Group Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N. Engl. J. Med. 2020; doi: 10.1056/NEJMoa2021436.

Vardavas C. I., Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tobacco Induced Disease. 2020. 18. 20.

Wiersinga W.J., Rhodes A., Cheng A.C. et al. Pathophy-siology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020. 324. 782-787.

Williamson E., Walker A.J., Bhaskaran K.J. et al. Open SAFELY: factors associated with COVID-19-rela-ted hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv. 2020.

Yang J. K. et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet. Med. 2006. 23. 623-628. doi: 10.1111/j.1464-5491.2006.01861.x.

Zhu L. et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020. 31. 1068-1077. doi: 10.1016/j.cmet.2020.04.021.





To help clinicians